<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04488159</url>
  </required_header>
  <id_info>
    <org_study_id>iMAGINE</org_study_id>
    <secondary_id>2020-000401-91</secondary_id>
    <nct_id>NCT04488159</nct_id>
  </id_info>
  <brief_title>Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer</brief_title>
  <acronym>iMAGINE</acronym>
  <official_title>iMmunoscore Associated Decision GuIdance for adjuvaNt Chemotherapy and Physical Exercise in Stage III Colon Cancer (iMAGINE): a Prospective, Randomized, Open-label, Multicenter, Phase III Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johannes Laengle, MD, PhD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall aim of this study is to prospectively validate the superiority of the Immunoscore
      as a decision guidance for adjuvant chemotherapy in stage III colon cancer patients, in
      comparison to the conventional TNM-based high- or low-risk classification.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2020</start_date>
  <completion_date type="Anticipated">June 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease-free survival (DFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Impact of Immunoscore stratification on DFS at 3 years (time from surgery to first observation of disease recurrence or death due to any cause)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>3 years</time_frame>
    <description>Impact of Immunoscore stratification on OS at 3 years (time from surgery to death due to any cause)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to recurrence (TTR)</measure>
    <time_frame>3 years</time_frame>
    <description>Impact of Immunoscore stratification on TTR at 3 years (time from surgery to disease recurrence)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment-related adverse events (AE)</measure>
    <time_frame>3 years</time_frame>
    <description>Impact of Immunoscore stratification on treatment-related AEs assessed according to the latest Common Terminology Criteria of Adverse Events (CTCAE).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>3 years</time_frame>
    <description>Impact of Immunoscore stratification on quality of life assessed by the latest version of the European Organization for Research and Treatment of Cancer (EORCT) Quality of Life Group (QLG) questionnaires C30 and CR29.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost analysis</measure>
    <time_frame>3 years</time_frame>
    <description>Impact of Immunoscore stratification on treatment-related costs, assessed by cost-effectiveness analysis (CEA) according to the latest Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1638</enrollment>
  <condition>Colon Cancer Stage III</condition>
  <arm_group>
    <arm_group_label>Immunoscore stratification</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Immunoscore low (I-Low; I0-1): 3 months CAPOX (oxaliplatin 130 mg/m2 IV over 2 h and capecitabine 1000 mg/m2 PO twice daily (days 1-14). 21-day treatment cycle.). Concomitantly, standardised physical excise (stair walking excise twice a week for 12 weeks), which will be monitored by an electronic sports device.
Immunoscore intermediate-high (I-IntHi; I2-3): 6 months FOLFOX (oxaliplatin 85 mg/m2 IV (on day 1) and folinic acid 200 mg/m2 IV over 2 h, followed by a bolus of fluorouracil 400 mg/m2 IV over 2-4 min, followed by fluorouracil 600 mg/m2 IV over 22 h (for 2 consecutive days). 14-day treatment cycle.)
Immunoscore high (I high; I4): no adjuvant treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TNM stratification</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TNM-based low-risk (pT1, pT2 or pT3 and pN1): 3 months CAPOX (oxaliplatin 130 mg/m2 IV over 2 h and capecitabine 1000 mg/m2 PO twice daily (days 1-14). 21-day treatment cycle.)
TNM-based high-risk (pT4 and/or pN2): 6 months FOLFOX (oxaliplatin 85 mg/m2 IV (on day 1) and folinic acid 200 mg/m2 IV over 2 h, followed by a bolus of fluorouracil 400 mg/m2 IV over 2-4 min, followed by fluorouracil 600 mg/m2 IV over 22 h (for 2 consecutive days). 14-day treatment cycle.)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>Tablet</description>
    <arm_group_label>Immunoscore stratification</arm_group_label>
    <arm_group_label>TNM stratification</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>Infusion</description>
    <arm_group_label>Immunoscore stratification</arm_group_label>
    <arm_group_label>TNM stratification</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluorouracil</intervention_name>
    <description>Infusion</description>
    <arm_group_label>Immunoscore stratification</arm_group_label>
    <arm_group_label>TNM stratification</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Infusion</description>
    <arm_group_label>Immunoscore stratification</arm_group_label>
    <arm_group_label>TNM stratification</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Immunoscore® assay</intervention_name>
    <description>Whole-slide tissue analysis of CD3+ and cytotoxic CD8+ T cells in the tumor and in the invasive margin</description>
    <arm_group_label>Immunoscore stratification</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Physical exercise</intervention_name>
    <description>Increasing stair walking exercise twice a week over 12 weeks total.</description>
    <arm_group_label>Immunoscore stratification</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  18-75 years of age

          -  All sexes

          -  Histologically confirmed stage III carcinoma of the colon

          -  Medical need for an adjuvant chemotherapy

          -  Suitable to withstand the course of an adjuvant chemotherapy

          -  Written informed consent form (ICF) for participation in the study

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1

        Exclusion Criteria:

          -  Neoadjuvant treatment

          -  Metastatic disease

          -  Pregnancy, breastfeeding or expectancy to conceive

          -  Disagreement of participants with reproductive potential to use contraception
             throughout the study period and for up to 180 days after the last dose of study
             therapy

          -  Uncontrolled or significant cardiovascular disease (myocardial infarction,
             uncontrolled angina, any history of clinically significant arrhythmias, QTc
             prolongation in males &gt; 450 ms and &gt; 470 ms in females, participants with history of
             myocarditis)

          -  Hepatitis B or C

          -  Human immunodeficiency virus (HIV)

          -  Immunodeficiency

          -  Allogeneic tissue or solid organ transplantation

          -  Systemic steroids or any other form of immunosuppressive therapy within 7 days prior
             to the first dose of study treatment

          -  Diagnosed and/or treated additional malignancy within 5 years of randomization, with
             the exception of curatively-treated basal cell or squamous cell carcinoma of the skin
             and/or curatively-resected in situ cervical and/or breast cancers

          -  Participants with serious or uncontrolled medical disorders

          -  Allergies and adverse drug reaction (history of allergy or hypersensitivity to study
             drug components, contraindications to any of the study drugs of the chemotherapy
             regimen)

          -  Other exclusion criteria: Prisoners or participants who are involuntarily
             incarcerated, participants who are compulsorily detained for treatment of either a
             psychiatric or physical (i.e. infectious disease) illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jérôme Galon, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Laboratory of Integrative Cancer Immunology, INSERM, Cordeliers Research Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Johannes Laengle, MD, PhD</last_name>
    <phone>+43 1 40400 69260</phone>
    <email>johannes.laengle@meduniwien.ac.at</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Michael Bergmann, MD</last_name>
    <phone>+43 1 40400 69260</phone>
    <email>michael.bergmann@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <contact>
      <last_name>Johannes Laengle, MD, PhD</last_name>
      <phone>+43 1 40400 69260</phone>
      <email>johannes.laengle@meduniwien.ac.at</email>
    </contact>
    <contact_backup>
      <last_name>Michale Bergmann, MD</last_name>
      <phone>+43 1 40400 69260</phone>
      <email>michael.bergmann@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Johannes Laengle, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Michael Bergmann, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 21, 2020</study_first_submitted>
  <study_first_submitted_qc>July 23, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 27, 2020</study_first_posted>
  <last_update_submitted>July 23, 2020</last_update_submitted>
  <last_update_submitted_qc>July 23, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Johannes Laengle, MD, PhD</investigator_full_name>
    <investigator_title>Sponsor-Investigator</investigator_title>
  </responsible_party>
  <keyword>Colon cancer</keyword>
  <keyword>Immunoscore</keyword>
  <keyword>CAPOX</keyword>
  <keyword>FOLFOX</keyword>
  <keyword>Physical exercise</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colonic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

